POPULARITY
30 episodes with ash annual meeting
25 episodes with ash annual meeting
10 episodes with ash annual meeting
7 episodes with ash annual meeting
5 episodes with ash annual meeting
10 episodes with ash annual meeting
7 episodes with ash annual meeting
9 episodes with ash annual meeting
7 episodes with ash annual meeting
8 episodes with ash annual meeting
8 episodes with ash annual meeting
9 episodes with ash annual meeting
7 episodes with ash annual meeting
7 episodes with ash annual meeting
3 episodes with ash annual meeting
3 episodes with ash annual meeting
3 episodes with ash annual meeting
2 episodes with ash annual meeting
3 episodes with ash annual meeting
2 episodes with ash annual meeting
2 episodes with ash annual meeting
3 episodes with ash annual meeting
2 episodes with ash annual meeting
21 episodes with ash annual meeting
2 episodes with ash annual meeting
2 episodes with ash annual meeting
2 episodes with ash annual meeting
4 episodes with ash annual meeting
2 episodes with ash annual meeting
2 episodes with ash annual meeting
2 episodes with ash annual meeting
2 episodes with ash annual meeting
9 episodes with ash annual meeting
9 episodes with ash annual meeting
7 episodes with ash annual meeting
7 episodes with ash annual meeting
Featuring an interview with Dr John P Leonard, including the following topics: First-line therapy for diffuse large B-cell lymphoma (DLBCL) with polatuzumab vedotin and R-CHP; impact of DLBCL cell of origin (0:00) Epcoritamab, glofitamab and other bispecific antibodies as initial therapy for large B-cell lymphoma (9:27) Sequencing chimeric antigen receptor T-cell therapy and bispecific antibodies for patients with relapsed/refractory (R/R) DLBCL (12:30) Approved and investigational bispecific antibodies for the treatment of DLBCL (15:24) Practical considerations for the administration of mosunetuzumab (22:03) Tafasitamab combined with lenalidomide/rituximab as second-line treatment for follicular lymphoma (FL); third- and later-line therapy options (24:33) Activity of Bruton tyrosine kinase inhibitors in FL and other non-Hodgkin lymphomas (31:27) Risk of infection for patients receiving bispecific antibodies (33:23) Chemotherapy-free regimens for the treatment of mantle cell lymphoma (MCL) (36:21) Current role of transplant in the treatment algorithm for MCL; potential integration of bispecific antibodies into therapy for R/R disease (41:23) Myths and misperceptions about the management of DLBCL, FL and MCL (47:29) CME information and select publications
Dr John P Leonard from Weill Cornell Medicine in New York, New York, reviews data presented at the 2024 ASH Annual Meeting and their implications for the treatment of non-Hodgkin lymphomas. CME information and select publications here.
Featuring a slide presentation and related discussion from Dr John P Leonard, including the following topics: Five-year analysis of the POLARIX trial of polatuzumab vedotin with R-CHP for previously untreated diffuse large B-cell lymphoma (0:00) Epcoritamab, glofitamab and other bispecific antibodies for large B-cell lymphoma (5:33) Circulating tumor DNA as an early outcome predictor in patients with large B-cell lymphoma receiving second-line lisocabtagene maraleucel in the TRANSFORM study (16:44) The bispecific antibodies mosunetuzumab and odronextamab as initial therapy for follicular lymphoma (FL) (19:27) The Phase III inMIND trial of tafasitamab in combination with lenalidomide/rituximab for recurrent FL (22:58) Updated results from studies of bispecific antibodies and chimeric antigen receptor T-cell therapy for relapsed/refractory FL (24:58) Updates from the Phase III TRIANGLE and ECOG-ACRIN EA4151 trials on the role of autologous stem cell transplant in the treatment of previously untreated mantle cell lymphoma (MCL) (27:48) Novel treatment approaches with Bruton tyrosine kinase inhibitors for patients with newly diagnosed MCL (30:53) CME information and select publications
Featuring a slide presentation and related discussion from Dr Raajit K Rampal, including the following topics: Overview of the current JAK inhibitor landscape (0:00) Factors predicting clinical benefit in patients with myelofibrosis (MF) receiving ruxolitinib (3:02) Clinical data supporting the use of fedratinib after prior ruxolitinib for MF (9:17) Emerging clinical findings on pelabresib in combination with ruxolitinib for previously untreated MF (12:13) Available clinical data with novel BET inhibitors (15:00) Utility of selinexor in combination with ruxolitinib for MF previously treated with ruxolitinib (16:50) Emerging efficacy and safety findings reported with imetelstat for MF (18:57) Clinical findings reported with the MDM2 inhibitor navtemadlin for MF (21:15) Available clinical data with the TGF-beta inhibitor elritercept for MF (24:05) Other novel agents and strategies under investigation for MF (26:06) CME information and select publications
Featuring an interview with Dr Raajit K Rampal, including the following topics: Clinical decision-making in the initiation and stopping of systemic therapy for myelofibrosis (MF) (0:00) Novel research strategies involving CDK4/6 inhibitors for MF (8:03) Implications of the JUMP study for clinical practice (10:00) Therapeutic switching strategies with JAK inhibitors for MF (12:17) Clinical rationale for the use of luspatercept and elritercept for MF (15:35) Emerging clinical data involving BET inhibitors for MF (16:57) Tolerability concerns with selinexor in patients with MF (20:01) Mechanism of and clinical data with the MDM2 inhibitor navtemadlin for MF (22:32) Additional novel strategies under clinical investigation for MF (25:52) Potential transformation of myeloproliferative neoplasms to acute myeloid leukemia (29:40) Management of polycythemia vera and essential thrombocythemia (34:27) General management principles for myeloproliferative neoplasms (37:53) CME information and select publications
Dr Raajit K Rampal from Memorial Sloan Kettering Cancer Center in New York, New York, discusses recent updates on available and novel treatment strategies for myelofibrosis. CME information and select publications here.
In today's episode, supported by Amgen, we had the pleasure of speaking with Ryan Cassaday, MD, an associate professor in the Clinical Research Division at the Fred Hutchinson Cancer Center and an associate professor in the Division of Hematology and Oncology at the University of Washington School of Medicine in Seattle, Washington. In our exclusive interview, Dr Cassaday discussed insights from several trials investigating blinatumomab (Blincyto) in patients with B-cell acute lymphoblastic leukemia (B-ALL) that were reported at the 2024 ASH Annual Meeting, including subgroup analyses of the phase 3 ECOG-ACRIN E1910 trial (NCT02003222). He also shared how findings from the phase 3 AALL1731 trial (NCT03914625) of blinatumomab plus chemotherapy in children with newly diagnosed B-ALL may be extrapolated to the adult B-ALL patient population.
In today's episode, supported by BeiGene, Alexey Danilov, MD, PhD, hosted a discussion with Susan M. O'Brien, MD, about key data updates with BTK inhibitors in patients with chronic lymphocytic leukemia (CLL) that were presented at the 2024 ASH Annual Meeting. Dr Danilov is the Marianne and Gerhard Pinkus Professor of Early Clinical Therapeutics, the medical director of the Early Phase Therapeutics Program for the Systems Clinical Trials Office, co-director of the Toni Stephenson Lymphoma Center, and a professor in the Division of Lymphoma at the Department of Hematology & Hematopoietic Cell Transplantation at City of Hope in Duarte, California. Dr O'Brien is the associate director for Clinical Science at the Chao Family Comprehensive Cancer Center, the medical director of the Sue & Ralph Stern Center for Clinical Trials & Research, and a professor of medicine in the Division of Hematology/Oncology in the University of California Irvine School of Medicine. In our exclusive interview, Drs Danilov and O'Brien discussed potentially practice-changing data with acalabrutinib (Calquence)–based regimens from the phase 3 AMPLIFY trial (NCT03836261) in CLL, key updates with zanubrutinib (Brukinsa) as monotherapy and in combination with sonrotoclax (BGB-11417) in patients with this disease, and practice-confirming findings with pirtobrutinib (Jaypirca) from the phase 3 BRUIN CLL-321 trial (NCT04666038) in patients with previously treated CLL.
Jurjen Versluis, Erasmus MC te Rotterdam, bespreekt met Marie José Kersten, Amsterdam MC, de laatste ontwikkelingen op het gebied van lymfomen die werden gepresenteerd tijdens de 66e ASH Annual Meeting. Aan bod komen onder andere de Triangle-, ECOG-ACRIN EA415-, ZUMA-2- en de inMIND-studie.
Jurjen Versluis bespreekt met Annemiek Broijl en Ruth Wester, allen Erasmus MC te Rotterdam, de laatste ontwikkelingen op het gebied van multipel myeloom die werden gepresenteerd tijdens de 66e ASH Annual Meeting.
Jurjen Versluis, Erasmus MC te Rotterdam, bespreekt met Mark-David Levin, Albert Schweitzer ziekenhuis te Dordrecht, de laatste ontwikkelingen op het gebied van chronische lymfatische leukemie (CLL) die werden gepresenteerd tijdens de 66e ASH Annual Meeting.
In this special crossover episode of Oncology Overdrive, we bring you Healio coverage from the ASH Annual Meeting and Exhibition, as well as Healio's top headlines from the meeting. Gwen L. Nichols, MD, reviews a panel discussion on how hematologists and oncologists can best address patients' concerns as AI's role in medicine invariably expands. :24 Thomas G. Knight, MD, addresses financial toxicity for people with blood cancer. 6:29 Charles S. Abrams, MD, discusses results of the HIBISCUS trial and its implications for vaso-occlusive events. 16:30 Read the full coverage here: AI in hematology: ‘The good, the bad and the ugly' Mitigating financial toxicity 'better than any drug' for people with cancer Etavopivat could offer ‘great benefit' in sickle cell disease ASH recognizes Judith Kleinerman, MD, with Exemplary Service Award GLP-1s reduce thrombosis risk among people with diabetes, regardless of obesity We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Disclosures: Jain reports no financial disclosures. Abrams reports he is chair of the ASH Research Collaborative's Sickle Cell Disease Clinical Trials Network Oversight Committee. Knight reports no relevant financial disclosures. Nichols reports no relevant financial disclosures.
In today's episode, supported by BeiGene, we had the pleasure of speaking with Mazyar Shadman, MD, MPH, about updates in zanubrutinib (Brukinsa)–focused research in chronic lymphocytic leukemia (CLL) that were presented at the 2024 ASH Annual Meeting. Dr Shadman is an associate professor in the Clinical Research Division and the medical director of Cellular Immunotherapy at the Fred Hutchinson Cancer Center in Seattle, Washington. In our exclusive interview, Dr Shadman discussed key findings and implications from several clinical trials investigating zanubrutinib as monotherapy and in combination with agents such as obinutuzumab (Gazyva), sonrotoclax (BGB-11417), and venetoclax (Venclexta) in patients with CLL and other B-cell malignancies.
Chronic Myelogenous Leukemia CancerCare Connect Education Workshops
- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts
- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts
- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts
- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts
Chronic Lymphocytic Leukemia CancerCare Connect Education Workshops
- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts
- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts
- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts
Marginal Zone Lymphoma CancerCare Connect Education Workshops
- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts
- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts
Waldenstrom’s Macroglobulinemia CancerCare Connect Education Workshops
- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts
Acute Lymphoblastic Leukemia CancerCare Connect Education Workshops
- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts
- Overview of Blood Cancers - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on: Leukemia, Lymphoma, Multiple Myeloma & Myeloproliferative Neoplasms (MPNs) - The Role of Precision Medicine & Clinical Trials - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Key Questions to Ask Your Health Care Team About Quality-of-Life Concerns - Questions for Our Panel of Experts
In today's episode, we had the pleasure of speaking with Andre Goy, MD, about key updates from the 2024 ASH Annual Meeting. Dr Goy is physician in chief of Hackensack Meridian Health Oncology Care Transformation Services, as well as the chairman, chief physician officer, and chief of the Lymphoma Division at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey. In our exclusive interview, Dr Goy discussed top hematologic oncology research conducted by his colleagues at the John Theurer Cancer Center and his predictions for the future of the field in 2025 and beyond.
Jurjen Versluis bespreekt met Bas Wouters, beiden Erasmus MC te Rotterdam, de laatste ontwikkelingen op het gebied van acute myeloïde leukemie (AML) die werden gepresenteerd tijdens de 66e ASH Annual Meeting.
This podcast Clinical Clip features a leading expert highlighting the latest advances in Acute Myeloid Leukemia(AML) treatments presented at the 66th ASH Annual Meeting and Exposition from December 7-10, 2024, in San Diego, CA.Launch Date: December 16, 2024Release Date: December 16, 2024Expiration Date: November 30, 2025FACULTYNaval Daver, MDDirector, Leukemia Research Alliance Program,Professor of MedicineDepartment of LeukemiaMD Anderson Cancer CenterThis podcast provides accredited continuing education credits. To receive your credit, please read the accreditation information provided at this link prior to listening to this podcast.
In this episode of #MovingMedicineForward – The Podcast, CTI experts Chad Jones & Eric Clayton discuss challenges in clinical research surrounding Acute Myeloid Leukemia (AML) & Multiple Myeloma (MM). They explore the complexities of designing & conducting clinical trials, the importance of site selection, & how CTI's expertise enhances trial outcomes. Additionally, they touch on key advancements to watch at the 66th American Society of Hematology Annual Meeting. During the episode, Eric explains how, “These are some of the first times that these therapies are being tried in human participants, & that innovative experimentation is what makes this work so exciting.” 0:22 Challenges in clinical research for Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM), with insights from CTI experts Chad Jones, Sr. Director of Project Management and Oncology Strategy Lead, and Eric Clayton, Clinical Project Manager III. 0:51 Overview of AML and MM, and why these diseases are particularly difficult to treat. 1:32 Key challenges in designing and conducting clinical trials for AML and MM. 3:19 How site selection and management impact trial success, and challenges Contract Research Organizations (CROs) face when recruiting qualified sites. 5:14 How CTI's expertise supports sponsors and improves trial outcomes. 6:38 The importance of maintaining proper chain of custody. 9:53 Key treatments and advancements in hematology to watch at the 66th ASH Annual Meeting. 10:33 Visit CTI at booth #454 at ASH. 10:41 Regulatory considerations for treatments and how CTI navigates this process for patients. 12:31 Collaboration between CROs, pharmaceutical companies, and academic institutions to accelerate research. 13:12 Unmet needs in AML and MM research and how the industry can address them. 14:16 Challenges in improving patient outcomes for MM and AML. 16:22 How CTI mitigates patient retention during clinical trials. 18:33 Strategies for recruiting critically ill MM and AML patients. 21:41 CTI is recruiting a Sr. Medical Director in Hematology/Oncology. Apply now: Senior Medical Director - Hematology/Oncology - Level Dependent Upon Experience | Join The CTI Team
Leading into the ASH Annual Meeting, Dr. Kami Maddocks, professor in the Division of Hematology at The Ohio State University and medical director of infusion services at The James Comprehensive Cancer Center, provides an in-depth analysis of advancements in non-Hodgkin lymphoma care, with a focus on aggressive B-cell lymphoma. She explores the evolving roles of immunotherapies like CAR-T cells and bispecific antibodies in high-risk patient populations, discusses the impact of cell-of-origin testing on frontline treatment decisions, and evaluates the latest data guiding choices between R-CHOP, transplant, and CAR-T therapy after first relapse. Dr. Maddocks also highlights the promise of BTK inhibitors and maintenance approaches in transforming patient outcomes, offering insights into the future of lymphoma treatment. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA
How best to treat patients with relapsed or refractory mantle cell lymphoma has been made clearer by a report from the multinational Phase III Sympatico Study, presented at the 65th ASH Annual Meeting and Exposition held in San Diego. Lead author Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at the University of Texas MD Anderson Cancer Center in Houston, told the conference how a combination of two targeted drugs—ibrutinib and venetoclax—improved outcomes.
A new targeted drug, revumenib, was found to increase response rates and survival in patients whose previously treated acute leukemias relapsed or were refractory to treatment. A Phase II clinical study found revumenib met its primary endpoint and was stopped early because of a high patient response rate and clinical efficacy. Revumenib acts on the hitherto untargeted histone-lysine N-methyltransferase 2A (KMT2A)-rearranged gene, which is present in around 1 in 10 acute leukemias among patients of all ages. The drug inhibits the interaction of the protein menin (associated with tumor suppression) and the KMT2A-fusion protein, which is believed to be an oncogenic driver in leukemias. OncTimesTalk correspondent Peter Goodwin heard the latest from lead study author Ibrahim Aldoss, MD, Associate Professor in the Division of Leukemia of the Department of Hematology & Hematopoietic Cell Transplantation at the City of Hope, after his report to the 65th ASH Annual Meeting & Exposition.
The process of identifying which patients with acute myeloid leukemia (AML) can benefit from allogeneic stem cell transplantation in first complete remission (CR1) has taken a step forward thanks to analysis of the UK NCRI AML17 and AML19 studies, reported at the 65th ASH Annual Meeting and Exposition. Patients who achieved molecular residual disease (MRD) negativity in their peripheral blood were at low risk of relapse, and had no benefit from allogeneic transplant in CR1, including those with the FMS-like tyrosine kinase 3 (FLT3) internal tandem duplication mutation of the NPM1 (nucleophosmin 1) gene, that is generally considered to be a marker of poor risk. Peter Goodwin spoke with Jad Othman, MBBS, from King's College London and the Guy's and St Thomas' Hospital in London, and now based at the Royal North Shore Hospital in Sydney, Australia. Othman explained how testing for the FLT3 mutation of the NPM1 gene can be used along with assessment of molecular MRD to help choose patients who can benefit from transplant and spare those for whom the risk/benefit ratio is adverse.
With no standard-of-care treatment for patients with high-risk relapsed/refractory follicular lymphoma, promising remissions have been observed in a Phase II study reported at the 65th ASH Annual Meeting and Exposition. The antibody-drug conjugate loncastuximab tesirine in combination with rituximab brought a very high complete metabolic response rate among patients satisfying the criteria for high risk, including relapse within 24 months. After talking at the ASH meeting, first author Juan Pablo Alderuccio, MD, Associate Professor of Medicine in the Sylvester Comprehensive Cancer Center's Division of Hematology at the University of Miami School of Medicine, discussed his findings with OncTimesTalk correspondent Peter Goodwin.
In this episode, Anthony and Bernie review the most impactful and interesting ALL abstracts at the 2023 ASH Annual Meeting. We dive into the nelarabine abstracts, calaspargase (cal-peg), and the evolution of the treatment of Ph+ ALL! Abstracts discussed: https://ash.confex.com/ash/2023/webprogram/Paper190141.html - COG AYA Outcomes (and silly nelarabine conclusions) https://ash.confex.com/ash/2023/webprogram/Paper177696.html - ATRIALL Nelarabine study https://ash.confex.com/ash/2023/webprogram/Paper179562.html - HyperCVAD + Nelarabine + PEG + venetoclax https://ash.confex.com/ash/2023/webprogram/Paper179192.html - ALL-TARGET Study in R/R T-ALL https://ash.confex.com/ash/2023/webprogram/Paper187694.html - Cal-PEG is toxic https://ash.confex.com/ash/2023/webprogram/Paper188064.html - Ponatinib + Blinatumomab https://ash.confex.com/ash/2023/webprogram/Paper187773.html - D-ALBA (Dasatinib + Blinatumomab) https://ash.confex.com/ash/2023/webprogram/Paper189632.html - GIMEMA (Dasatinib or Ponatinib + Blinatumomab)
Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on December 19, 2023 Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, returns to discuss highlights from the 65th American Society of Hematology (ASH) Annual Meeting in December 2023, including updates on blood cancer research, treatment, and clinical trials in leukemia, lymphoma, myeloma, MDS, and MPNs. Tune in to this informative update today!
The latest episode of the DDW Highlights podcast is now available to listen to below. DDW's Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. Our news highlights this week focus on haematology, thanks in part to a number of key announcements at the 65th American Society for Hematology meeting (ASH) Annual Meeting, including real-world evidence on the use of CAR-T therapies in blood cancers and new data for myeloma and lymphoma treatments. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.
Chronic Myelogenous Leukemia CancerCare Connect Education Workshops
- Overview of Blood Cancers, in the Context of COVID-19 - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma and Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Talking with Your Health Care Team about Your Treatment Options - Communicating with Your Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for These Appointments - Key Questions to Ask Your Health Care Team - Quality-of-Life Concerns - Questions for Our Panel of Experts
- Overview of Blood Cancers, in the Context of COVID-19 - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma and Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Talking with Your Health Care Team about Your Treatment Options - Communicating with Your Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for These Appointments - Key Questions to Ask Your Health Care Team - Quality-of-Life Concerns - Questions for Our Panel of Experts
Chronic Lymphocytic Leukemia CancerCare Connect Education Workshops
- Overview of Blood Cancers, in the Context of COVID-19 - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma and Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Talking with Your Health Care Team about Your Treatment Options - Communicating with Your Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for These Appointments - Key Questions to Ask Your Health Care Team - Quality-of-Life Concerns - Questions for Our Panel of Experts
- Overview of Blood Cancers, in the Context of COVID-19 - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma and Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Talking with Your Health Care Team about Your Treatment Options - Communicating with Your Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for These Appointments - Key Questions to Ask Your Health Care Team - Quality-of-Life Concerns - Questions for Our Panel of Experts
- Overview of Blood Cancers, in the Context of COVID-19 - New Research Presented at ASH - Disease-Specific Treatment Updates from ASH on Leukemia, Lymphoma, Multiple Myeloma and Myeloproliferative Neoplasms (MPN) - The Role of Precision Medicine & Clinical Trials - Talking with Your Health Care Team about Your Treatment Options - Communicating with Your Health Care Team with Telehealth/Telemedicine Appointments - Guidelines to Prepare for These Appointments - Key Questions to Ask Your Health Care Team - Quality-of-Life Concerns - Questions for Our Panel of Experts
This past weekend, the CURE® staff was busy covering the American Society of Hematology (ASH) Annual Meeting. ASH is the largest blood cancer conference in the country, and thousands of abstracts were presented. Now, we're bringing you some of the highlights from the conference. And, to view all of our conference coverage, be sure to check out curetoday.com/conference Navitoclax Plus Jakafi Improves Spleen Volume Reductions in Myelofibrosis Spleen enlargement is a common and often problematic symptom of myelifbrosis. However, recent findings from the phase 3 TRANSFORM-1 trial found that combining the novel drug, navitoclax with Jakafi was successful in reducing spleen volume in this patient population. The main outcome that the researchers were looking at in this study was the percentage of patients who had a spleen volume reduction of 35% or more at certain time points. Findings showed that by week 24, 64.2% of patients who had the navitoclax regimen experienced this level of spleen reduction, compared to only 31.5% of patients who received placebo plus Jakafi — that's a significant overall difference of 31%. Navitoclax is not currently approved in any indication, but AbbVie, the pharmaceutical company behind the agent, plans to submit the drug for FDA approval in 2023, pending study results. Brukinsa Lengthens Time to Progression in Relapsed/Refractory CLL, SLL There are currently three BTK inhibitors for the treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL and SLL, respectively), though a lack of research exists that compares these drugs head-to-head. Now, the phase 3 ALPINE trial was the first study to directly compare two BTK inhibitors, Brukinsa and Imbruvica, in patients with relapsed or refractory CLL or SLL. Findings showed that after about 39 months of follow-up, patients given Brukinsa tended to live longer before death or disease progression — a statistic experts refer to as “progression-free survival.” In the general patient population, Brukinsa reduced the risk of disease progression by 32%, and for patients with 17p deletion and/or TP53 mutations — subtypes that typically indicate aggressive disease — there was a 48% reduction in the risk of disease progression. Abecma May Improve Quality of Life in Previously Treated Myeloma The phase 3 KarMMA-3 trial showed that Abecma significantly improved symptoms, functioning and health-related quality of life in patients with relapsed or refractory multiple myeloma who previously underwent two to four prior treatments. Abecma is a CAR-T cell therapy, which is a newer type of treatment for blood cancers. It involves taking patients' blood out, and re-engineering their T cells to find and fight cancer. After they're multiplied, those new T cells are infused back into the patient. Findings from the KarMMA-3 trial showed that Abecma led to improvements in fatigue and pain compared with other standard regimens in this patient population.
Blood cancer treatments — and one treatment type, in particular — were the point of much discussion last week. The FDA said that it is investigating instances of secondary malignancies in patients with blood cancers treated with CAR-T cell therapy. Also, the drug manufacturer for a novel CAR-T cell therapy submitted an application to introduce the treatment into the United States market. Blood cancers will continue to be a hot topic this week, as later in the week we'll be covering the American Society of Hematology Annual Meeting. And before that, we'll also be covering the San Antonio Breast Cancer Symposium. Chance or CAR-T: Expert Weighs in on FDA Investigation One of the biggest headlines in the cancer space last week was that the Food and Drug Administration (FDA) announced that they are investigating instances of T-cell malignancies — such as CAR-positive lymphoma — occurring in patients with blood cancers that were treated with CAR-T cell therapy. CAR-T cell therapy is a newer type of blood cancer treatment that involves extracting patients' blood and reengineering their immune T cells to find and fight cancer. Those new T cells are then multiplied and infused back into the patient. Since the first CAR-T cell product was approved in 2017, this treatment modality has drastically improved outcomes for patients with certain types of blood cancers. It's worth mentioning that the FDA's Nov. 28 report about T-cell malignancies did not definitively say that CAR-T cell therapies are directly causing secondary diseases. They also did not mention the frequency at which these T-cell malignancies are occurring. I spoke with Dr. John Lister, who said that perhaps it's the manufacturing process that could be the root cause, but perhaps it is also just chance, as research has shown that many patients with cancer hold a higher risk of developing a second cancer. For now, we're just going to have to wait and see what further data tells us. FDA Biologics License Application Filed for Obe-Cel for Adult R/R B-ALL Also in CAR-T cell therapy news, last week a pharmaceutical company submitted a Biologics License Application to the FDA for their CAR-T cell therapy, obe-cel to be used for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). When a pharmaceutical company files a Biologics License Application to the FDA, they're essentially asking the agency to allow them to bring the drug to the market. The company submitting the drug must provide the FDA with multiple pieces of information, including findings from preclinical and clinical studies showing that the drug is safe. In this instance, the pharmaceutical company cited data from the FELIX study, from which, early data showed that 76% if patients responded to the therapy, including 54.3% who had a complete response, meaning that their disease essentially disappeared. Now, updated findings from the trial will be presented at the upcoming ASH Annual Meeting happening next week.
Featuring perspectives from Dr Jacob Laubach, including the following topics: Evolution of first-line treatment for multiple myeloma (MM) (0:00) Perspectives on the future of bispecific antibody and chimeric antigen receptor (CAR) T-cell therapy for the management of MM (13:27) ASH 2022 updates on front-line management of MM for transplant-ineligible patients (18:35) ASH 2022 updates on the use of isatuximab-containing regimens for newly diagnosed and relapsed/refractory (R/R) MM (24:57) ASH 2022 updates on the clinical efficacy of CAR T-cell therapy for R/R MM; perspectives on the future of belantamab mafodotin (35:05) ASH 2022 updates on the efficacy and safety of teclistamab for R/R MM (46:33) Bispecific antibody therapy administration and patient education (52:41) ASH 2022 updates on investigational bispecific antibodies and other novel therapies for MM (1:00:17) CME information and select publications
Dr Jacob Laubach from the Dana-Farber Cancer Institute discusses key presentations in multiple myeloma from the 2022 ASH Annual Meeting. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASH23/MM).
Featuring a discussion on newly presented data in multiple myeloma from the 2022 ASH Annual Meeting, with Dr Jacob Laubach, moderated by Dr Neil Love.
Featuring an interview with Dr John Allan, including the following topics: • Update on key studies of acalabrutinib in the front-line setting (0:00) • Updated data from the GLOW study: First-line fixed-duration ibrutinib and venetoclax compared to chlorambucil and Obinutuzumab (21:11) • Treatment outcomes after achieving undetectable minimal residual disease (MRD) with first-line ibrutinib and venetoclax: Updated analysis of the CAPTIVATE trial (35:06) • Ibrutinib/venetoclax with MRD-driven duration of treatment: Updated analysis of the FLAIR trial (48:08) • Acalabrutinib with venetoclax and obinutuzumab for previously untreated chronic lymphocytic leukemia (CLL) in a population enriched for high-risk disease (50:49) • Risk factors to predict failure of therapy using fixed-duration venetoclax/obinutuzumab (53:22) • Updates on the ALPINE and BRUIN studies of zanubrutinib and pirtobrutinib, respectively, for relapsed/refractory CLL (56:15) • Emerging data with novel Bcl-2 inhibitors (1:11:26) • Evolving data with subcutaneous epcoritamab for patients with Richter's transformation and CLL (1:14:37) CME information and select publications
Dr John Allan from Weill Cornell Medicine in New York City discusses the most important chronic lymphocytic leukemia studies presented at ASH 2022. CME information and select publications here (http://www.researchtopractice.com/OncologyTodayPostASH23/CLL).
Featuring a discussion on chronic lymphocytic leukemia studies presented at ASH 2022 with Dr John Allan, moderated by Dr Neil Love.
© 2020-2025 Ivy Podcast Discovery LLC
